Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Psilocybin in Treatment-Resistant Depression (P-TRD)
2017-003288-36Phase 2Unknown
- Sponsor
- COMPASS Pathways
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by COMPASS Pathways. Primary endpoint: Primary: Change in MADRS total score at 3 weeks. Status: unknown.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-003288-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003288-36.